Investigational Drug Details
| Drug ID: | D240 |
| Drug Name: | Nicotinamide |
| Synonyms: | 3-pyridinecarboxamide; Niacinamide; Nicotinamide; Nicotinic acid amide; Nicotinic amide; β-pyridinecarboxamide |
| Type: | Chemical drug |
| DrugBank ID: | DB02701 |
| DrugBank Description: | An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. |
| PubChem ID: | 936 |
| CasNo: | 98-92-0 |
| Repositioning for NAFLD: | No |
| SMILES: | C(=O)(N)c1cccnc1 |
| Structure: |
|
| InChiKey: | DFPAKSUCGFBDDF-UHFFFAOYSA-N |
| Molecular Weight: | 122.127 |
| DrugBank Targets: | Exotoxin A product of; L-lactate dehydrogenase A chain; Poly [ADP-ribose] polymerase 1 binder; NAD-dependent protein deacylase sirtuin-5, mitochondrial; ADP-ribosyl cyclase 2 product of |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | PARP inhibitor |
| Therapeutic Category: | Metabolic disorder drug |
| Clinical Trial Progress: | Phase 2 completed (NCT03850886: Nicotinamide at a dose of 1000 mg daily was tolerable, improved metabolic abnormalities and QOL of diabetic NAFLD patients with no effect on liver fibrosis or steatosis.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0770 | NCT03850886 | Phase 2 | Not recruiting | No Results Available | 30/01/2019 | 12 December 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | Details |
| A00091 | 35222903 | Ther Adv Chronic Dis | Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. | Details |
| A00251 | 35164657 | Bioengineered | Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. | Details |
| A01391 | 34762911 | J Biol Chem | Hepatocyte-specific perturbation of NAD+ biosynthetic pathways in mice induces reversible nonalcoholic steatohepatitis-like phenotypes. | Details |
| A01524 | 34708231 | Sheng Li Xue Bao | [The role of SIRT6 in nonalcoholic steatohepatitis]. | Details |
| A01587 | 34684533 | Nutrients | Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice. | Details |
| A01608 | 34680557 | Biomedicines | Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet. | Details |
| A03278 | 34063865 | Metabolites | The Role of AKR1B10 in Physiology and Pathophysiology. | Details |
| A03609 | 33932956 | J Physiol | NAD+ and NAFLD - caution, causality and careful optimism. | Details |
| A03768 | 33870623 | Mol Nutr Food Res | Nicotinamide Protects Against Diet-Induced Body Weight Gain, Increases Energy Expenditure, and Induces White Adipose Tissue Beiging. | Details |
| A04109 | 33754067 | Theranostics | NAD+-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin. | Details |
| A04522 | 33588049 | Free Radic Biol Med | Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. | Details |
| A04731 | 33524747 | Chemosphere | Thiamethoxam induces nonalcoholic fatty liver disease in mice via methionine metabolism disturb via nicotinamide N-methyltransferase overexpression. | Details |
| A05022 | 33408299 | J Toxicol Sci | Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase. | Details |
| A05131 | 33362385 | World J Gastroenterol | Untargeted metabolomics characteristics of nonobese nonalcoholic fatty liver disease induced by high-temperature-processed feed in Sprague-Dawley rats. | Details |
| A05268 | 33318872 | J Adv Res | Implications of hydrogen sulfide in liver pathophysiology: Mechanistic insights and therapeutic potential. | Details |
| A05645 | 33177546 | Sci Rep | PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat. | Details |
| A05828 | 33105604 | Int J Mol Sci | Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor. | Details |
| A06028 | 33035588 | Life Sci | Nicotinamide and ascorbic acid nanoparticles against the hepatic insult induced in rats by high fat high fructose diet: A comparative study. | Details |
| A06119 | 32998280 | Metabolites | Neuronal Lipoprotein Lipase Deficiency Alters Neuronal Function and Hepatic Metabolism. | Details |